Your CRL just landed.

Now, cut your response time by
half.

Extract every deficiency, map it to your data, and draft a source-cited response, all inside your existing Databricks Lakehouse.

Active Alerts & Milestones

4

CMC Item #11: Batch record deviation at Facility A requires CAPA documentation. Assigned to CMC team — 3 days overdue.

CMC3 days ago

Clinical Item #4: Sensitivity analysis for primary endpoint (PFS) running. ETA: 18 hours. 3 parallel scenarios queued in Databricks Workflows.

Clinical18h ago

Safety Items #7, #8, #9: Integrated safety narrative draft complete. Medical writing review in progress.

Safety1 day ago

Type A Meeting: FDA meeting confirmed for July 15. Briefing document auto-generated from current response matrix. Review recommended.

Regulatory2 days ago
John Doe Regulatory Affairs

Submission NDA 217045 Overview

Drug: Veloxamab Indication: NSCLC

Response deadline:

27 days remaining

Overview
CRL Ingestion
Safety Review
RegulatoryAI

TOTAL CRL ITEMS

Extracted by AI in 4 min

14

ITEMS RESOLVED

43% complete

6

IN PROGRESS

On track

5

TIME TO RESUBMIT

vs. 14 mo industry avg

5.2 mo

Response Timeline vs. Industry Benchmark

Projected completion by activity area

ActivityIndustry avg Accelerated
CRL Gap Analysis
3 weeks
Clinical Reanalysis
3 wk
Safety Narrative
2 wk
CMC Response
4 wk
Document Assembly
1 wk
Time savings: 8.8 months · Est. revenue impact: $704M

CRL Items by Category

Classified and linked to data assets automatically

14Items
Clinical/Statistical (6)
Safety (4)
CMC / Manufacturing (2)
Labeling (2)

Data Readiness

Data exists in Lakehouse11 / 14
New data required3 / 14

Other Submissions

Sumissions name Deadline Creation date Status Issues
NDA340272435
Jan 15, 2027 Jan 15, 2025 Pending -
NDA340272435
Aug 28, 2026 Jan 15, 2025 In Progress 15
NDA340272435
Oct 22, 2026 Jan 15, 2025 In Progress 15
NDA340272435
Jan 15, 2026 Jan 15, 2025 Resolved 0
NDA340272435
Jan 21, 2026 Jan 15, 2025 Resolved 0

No submissions match your search.

Showing 1-10 of 50 results

THE PROBLEM

Time is money when you receive a CRL.

📄

Deficiencies buried in PDFs

Regulatory affairs manually reads every deficiency and builds a tracker by hand.

Gap analysis alone takes 6 weeks.

Even with governed, unified data, most response processes remain highly manual.

📈

Reanalyses executed one at a time

Biostatisticians run sensitivity analyses sequentially; one finishes, then the next one starts.

That queue can add up to 3 months.

💰

Data scattered across
disconnect systems

Pulling one integrated safety dataset across trials takes weeks on its own.

Disconnect systems can add 6 or more months.

BUSINESS RESULTS

0months
Saved on average
$0M
Revenue recovered
00×
Return on investment

Seven months faster.
That changes who gets to market first.

For a drug with a projected impact of $1B at peak-sales, every month between a CRL and resubmission costs roughly $83M in deferred revenue.

THE SOLUTION

The same response.

Five months instead of twelve.

One workflow, four stages, start to finish: your data is already unified in Databricks, this is the workflow layer that gets built on top of that.

CRL Ingestion - Step 1
CRL Ingestion - Step 2
CRL Ingestion - Step 3
CRL Ingestion - Step 4
6 Weeks → Under 4 Min.
CRL Intelligence

AI reads the letter the moment it's uploaded, classifies every deficiency by type, and links each one to the data tables and studies it references.

6 Weeks → 2 Days
Gap Analysis

Unity Catalog checks every item against your existing data automatically, flagging what's missing and saving weeks of back-and-forth.

3 Months → 3 Weeks
Reanalysis Engine

50+ sensitivity analyses run simultaneously on Spark. MLflow audit trail for GxP reproducibility.

8 Weeks → 2 Weeks
Safety Review

Safety data unifies across trials through a pre-built pipeline, with an AI-drafted narrative grounded in the actual dataset.

RegulatoryAI throughout the entire process.

John Doe Regulatory Affairs

Submission NDA 217045 Overview

Drug: Veloxamab Indication: NSCLC

Response deadline:

27 days remaining

Overview
CRL Ingestion
RegulatoryAI

RegulatoryAI — Retrieval-Augmented Assistant

Answers grounded in your NDA, CRL, and FDA guidances. All responses cite source documents.

Hello. I'm RegulatoryAI, your CRL response assistant. I have access to your full NDA, the March 2026 CRL, all FDA guidance documents relevant to this submission, and your prior meeting minutes with FDA. How can I help you build your response?
Ask about any CRL item, NDA content, or FDA guidance…

RegulatoryAI drafts the response as the other stages finish, not after. Every line traces back to your NDA or FDA guidance

BUILT ON DATABRICKS

Every stage runs on the Databricks investment you already made.

No new platform. No migration. Every module runs on components already in your Lakehouse.

Databricks Workflows — orchestrating governance and item-to-data mapping across every stage of the SunnyCRL CRL response process
Databricks Model Serving — governance and item-to-data mapping for AI-assisted CRL response generation in SunnyCRL

The same Lakehouse, doing more of the work that used to sit outside it.

Pharmaceutical pill bottle background — SunnyCRL Response accelerates FDA CRL responses from a year to months using your existing Databricks environment

Make your next CRL response
take months, not a year.

Talk to our team about a 2-week proof of value on your own Databricks environment.